The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.875
Bid: 2.75
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.25 (9.091%)
Open: 2.875
High: 3.00
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Jefferies Starts Metro Bank With Buy Rating

Thu, 10th Mar 2016 09:33

LONDON (Alliance News) - The following shares received analyst recommendations Thursday morning and Wednesday:
----------
FTSE 100
----------
GOLDMAN CUTS ROLLS-ROYCE TO 'NEUTRAL' ('BUY') - TARGET 725 (711) PENCE
----------
PANMURE RAISES RSA INSURANCE TO 'HOLD' ('SELL') - TARGET 428 (385) PENCE
----------
CITIGROUP CUTS NEXT PRICE TARGET TO 7,400 (7,800) PENCE
----------
TRADERS: KEPLER CHEUVREUX STARTS BP WITH 'REDUCE'
----------
JEFFERIES RAISES WHITBREAD TO 'HOLD' ('UNDERPERFORM') - TARGET 3,600 (4,100)P
----------
DEUTSCHE BANK RAISES PRUDENTIAL PRICE TARGET TO 1620 (1565) PENCE - 'HOLD'
----------
BERNSTEIN CUTS RBS TO 'MARKET-PERFORM' ('OUTPERFORM') - TARGET 230 (450) PENCE
----------
TRADERS: MACQUARIE RAISES INTU PROPERTIES TO 'OUTPERFORM' ('NEUTRAL')
----------
MORGAN STANLEY CUTS ASTRAZENECA PRICE TARGET TO 5000 (5300) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS SCHRODERS PRICE TARGET TO 3,275 (3,350) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS ASHTEAD GROUP PRICE TARGET TO 1,140 (1,240) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES SSE TO 'OVERWEIGHT' ('UNDERWEIGHT') - TARGET 1,550 (1,280) PENCE
----------
JPMORGAN RAISES CENTRICA TO 'NEUTRAL' ('UNDERWEIGHT') - TARGET 230 PENCE
----------
FTSE 250
----------
CITIGROUP CUTS RESTAURANT GROUP TO 'SELL' ('NEUTRAL') - TARGET 370 (575)P
----------
GOLDMAN CUTS RESTAURANT GROUP TO 'NEUTRAL' ('CONVICTION BUY')
----------
BERENBERG CUTS RESTAURANT GROUP TO 'HOLD' ('BUY') - TARGET 550 (750) PENCE
----------
BARCLAYS CUTS RESTAURANT GROUP PRICE TARGET TO 475 (760) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS CUTS G4S TO 'EQUAL WEIGHT' ('OVERWEIGHT') - TARGET 200 (310) PENCE
----------
BARCLAYS CUTS CLOSE BROTHERS PRICE TARGET TO 1,300 (1,375)P - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES CAIRN ENERGY PRICE TARGET TO 190 (180) PENCE - 'EQUAL WEIGHT'
----------
DEUTSCHE BANK RAISES CAIRN ENERGY PRICE TARGET TO 220 (200) PENCE - 'BUY'
----------
EXANE BNP RAISES CAIRN ENERGY PRICE TARGET TO 201 (176) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS G4S PRICE TARGET TO 180 (240) PENCE - 'NEUTRAL'
----------
RBC CAPITAL CUTS G4S PRICE TARGET TO 170 (190) PENCE - 'UNDERPERFORM'
----------
GOLDMAN RAISES AUTO TRADER GROUP TO 'BUY' ('NEUTRAL') - TARGET 443 (415) PENCE
----------
TRADERS: PEEL HUNT RAISES SAVILLS TO 'ADD' ('HOLD')
----------
LIBERUM CUTS COBHAM PRICE TARGET TO 270 (330) PENCE - 'BUY'
----------
HSBC RAISES PETROFAC PRICE TARGET TO 1,150 (900) PENCE - 'BUY'
----------
Liberum Ups Laird Target To 350p From 325p, Keeps Hold
----------
SHORE CAPITAL CUTS RATHBONE BROS TO 'HOLD' ('BUY') - TARGET 2350 (2840) PENCE
----------
JPMORGAN CUTS DRAX GROUP PRICE TARGET TO 360 (370) PENCE - 'NEUTRAL'
----------
JPMORGAN CUTS CLOSE BROTHERS PRICE TARGET TO 1,600 (1,630) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES ESURE GROUP PRICE TARGET TO 287 (286) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS DRAX GROUP PRICE TARGET TO 260 (370) PENCE - 'NEUTRAL'
----------
MORGAN STANLEY RAISES WILLIAM HILL PRICE TARGET TO 425 (400)P - 'EQUAL-WEIGHT'
----------
MORGAN STANLEY CUTS UNITE GROUP PRICE TARGET TO 770 (780) PENCE - 'OVERWEIGHT'
----------
MAIN MARKET AND AIM
----------
Jefferies Initiates Metro Bank With Buy, 3,000.00p Price Target
----------
PANMURE ADDS PANTHEON RESOURCES TO CONVICTION LIST - 'BUY' - TARGET 170 PENCE
----------
PANMURE RAISES HILL & SMITH PRICE TARGET TO 950 (850) PENCE - 'BUY'
----------
PANMURE RAISES ALLERGY THERAPEUTICS PRICE TARGET TO 53 (51) PENCE - 'BUY'
----------
RBC CAPITAL CUTS FIRESTONE DIAMONDS TARGET TO 35 (40)P - 'SECTOR PERFORM'
----------
RBC CAPITAL RAISES NOVAE GROUP PRICE TARGET TO 975 (950) PENCE - 'OUTPERFORM'
----------
RBC CAPITAL CUTS GEM DIAMONDS PRICE TARGET TO 170 (190) PENCE - 'OUTPERFORM'
----------
RBC CAPITAL CUTS GENEL ENERGY TO 'SECTOR PERFORM' ('OUTPERFORM') CUTS PRICE TARGET TO 115 (400) PENCE
----------
Nomura Ups Stock Spirits Group Target To 150p From 140p, Keeps Neutral
----------
BERENBERG RAISES TYMAN PRICE TARGET TO 330 (310) PENCE - 'BUY'
----------
LIBERUM RAISES TYMAN PRICE TARGET TO 335 (310) PENCE - 'BUY'
----------
UBS RAISES HOCHSCHILD MINING PRICE TARGET TO 120 (80) PENCE - 'BUY'
----------
BERENBERG RAISES NICHOLS PRICE TARGET TO 1,475 (1,450) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
27 Mar 2024 16:13

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
27 Mar 2024 11:02

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
12 Mar 2024 14:06

Allergy Therapeutics starts dosing patients in peanut allergy trial

(Alliance News) - Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.

Read more
1 Mar 2024 15:49

UK shareholder meetings calendar - next 7 days

Monday 4 March 
Ascent Resources PLCGM re bonus issue of preference shares
JPMorgan Emerging Europe, Middle East & Africa Securities PLCAGM
Lexington Gold LtdAGM
Tuesday 5 March 
Ajax Resources PLCGM re extension of investment mandate
Beowulf Mining PLCGM re capital raise
CC Japan Income & Growth Trust PLCAGM
Driver Group PLCAGM
Edinburgh Worldwide Investment Trust PLCAGM
Jersey Electricity PLCAGM
Wednesday 6 March 
Ecofin Global Utilities & Infrastructure Trust PLCAGM
Mila Resources PLCAGM
Paragon Banking Group PLCAGM
Thursday 7 March 
Asia Strategic Holdings LtdAGM
CT UK Capital & Income Investment Trust PLCAGM
Henderson Opportunities Trust PLCAGM
XPS Pensions Group PLCGM re directors' remuneration policy 2024
Friday 8 March 
Allergy Therapeutics PLCAGM
All Things Considered Group PLCAGM
Chenavari Toro Income Fund LtdAGM
Neo Energy Metals PLCAGM
Schroder UK Mid Cap Fund PLCAGM
Silverwood Brands PLCGM re proposed share capital reduction
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
14 Feb 2024 10:22

Allergy Therapeutics forecasts revenue drop but trials going well

(Alliance News) - Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further funding soon.

Read more
5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
30 Jan 2024 10:38

Allergy Therapeutics resumes trading on AIM; annual revenue plunges

(Alliance News) - Allergy Therapeutics PLC on Tuesday resumed trading on AIM after the release of its annual results.

Read more
27 Dec 2023 14:17

IN BRIEF: Allergy Therapeutics amends facility, plans warrant issue

Allergy Therapeutics PLC - Sussex-based biotechnology company specialising in allergy vaccines - Shares rise as firm enters amendment to the facility agreement it reached in early April with SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Deal provides Allergy Therapeutics with a GBP40 million secured loan facility of which GBP32.5 million is uncommitted. Facility is available to drawdown between January 15 and the same day in 2026, with interest payable semi-annually at 12% per year and a January 15, 2027 repayment date.

Read more
15 Dec 2023 21:09

EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
13 Dec 2023 10:11

Allergy Therapeutics shares jump as hails grass allergy jab data

(Alliance News) - Allergy Therapeutics PLC on Wednesday said that phase-3 trials of its grass allergy injection yielded positive results, moving the product closer to market entry.

Read more
13 Dec 2023 09:55

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
14 Nov 2023 11:56

Allergy Therapeutics says allergy therapy trial meets primary endpoint

(Alliance News) - Allergy Therapeutics PLC on Tuesday said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary endpoint.

Read more
14 Nov 2023 10:59

AIM WINNERS & LOSERS: Renalytix revenue halves; DP Poland trades well

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
6 Nov 2023 12:33

IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.